![[PUBLICATION PRECELLYS] Qualification of tumour mutational burden by targeted next-generation sequencing as a biomarker in hepatocellular carcinoma Bertin Technologies 49829](https://www.bertin-technologies.com/wp-content/uploads/2022/08/Group-56.svg)
![[PUBLICATION PRECELLYS] Qualification of tumour mutational burden by targeted next-generation sequencing as a biomarker in hepatocellular carcinoma Bertin Technologies 49831](https://www.bertin-technologies.com/wp-content/uploads/2022/08/Group-57.svg)
![[PUBLICATION PRECELLYS] Qualification of tumour mutational burden by targeted next-generation sequencing as a biomarker in hepatocellular carcinoma Bertin Technologies 51209](https://www.bertin-technologies.com/wp-content/uploads/2022/09/Group-cbrn-1.svg)
![[PUBLICATION PRECELLYS] Qualification of tumour mutational burden by targeted next-generation sequencing as a biomarker in hepatocellular carcinoma Bertin Technologies 49833](https://www.bertin-technologies.com/wp-content/uploads/2022/08/Group-58.svg)
![[PUBLICATION PRECELLYS] Qualification of tumour mutational burden by targeted next-generation sequencing as a biomarker in hepatocellular carcinoma Bertin Technologies 49835](https://www.bertin-technologies.com/wp-content/uploads/2022/08/Group-59.svg)
![[PUBLICATION PRECELLYS] Qualification of tumour mutational burden by targeted next-generation sequencing as a biomarker in hepatocellular carcinoma Bertin Technologies 51211](https://www.bertin-technologies.com/wp-content/uploads/2022/09/Group-space-big-science-1.svg)
![[PUBLICATION PRECELLYS] Qualification of tumour mutational burden by targeted next-generation sequencing as a biomarker in hepatocellular carcinoma Bertin Technologies 51200](https://www.bertin-technologies.com/wp-content/uploads/2022/09/Group-optronics.svg)
![[PUBLICATION PRECELLYS] Qualification of tumour mutational burden by targeted next-generation sequencing as a biomarker in hepatocellular carcinoma Bertin Technologies 51204](https://www.bertin-technologies.com/wp-content/uploads/2022/09/Group-optomechanical.svg)
![[PUBLICATION PRECELLYS] Qualification of tumour mutational burden by targeted next-generation sequencing as a biomarker in hepatocellular carcinoma Bertin Technologies 51202](https://www.bertin-technologies.com/wp-content/uploads/2022/09/Group-photonics.svg)
![[PUBLICATION PRECELLYS] Qualification of tumour mutational burden by targeted next-generation sequencing as a biomarker in hepatocellular carcinoma Bertin Technologies 51212](https://www.bertin-technologies.com/wp-content/uploads/2022/09/Group-application-center.svg)
![[PUBLICATION PRECELLYS] Qualification of tumour mutational burden by targeted next-generation sequencing as a biomarker in hepatocellular carcinoma Bertin Technologies 51214](https://www.bertin-technologies.com/wp-content/uploads/2022/09/Group-distributor-map.svg)
![[PUBLICATION PRECELLYS] Qualification of tumour mutational burden by targeted next-generation sequencing as a biomarker in hepatocellular carcinoma Bertin Technologies 51216](https://www.bertin-technologies.com/wp-content/uploads/2022/09/Group-register-1.svg)
![[PUBLICATION PRECELLYS] Qualification of tumour mutational burden by targeted next-generation sequencing as a biomarker in hepatocellular carcinoma Bertin Technologies 51218](https://www.bertin-technologies.com/wp-content/uploads/2022/09/Group-media.svg)
![[PUBLICATION PRECELLYS] Qualification of tumour mutational burden by targeted next-generation sequencing as a biomarker in hepatocellular carcinoma Bertin Technologies 51220](https://www.bertin-technologies.com/wp-content/uploads/2022/09/Group-faq.svg)
![[PUBLICATION PRECELLYS] Qualification of tumour mutational burden by targeted next-generation sequencing as a biomarker in hepatocellular carcinoma Bertin Technologies 69984](https://www.bertin-technologies.com/wp-content/uploads/2024/06/about-us-2.png){kind=small}
![[PUBLICATION PRECELLYS] Qualification of tumour mutational burden by targeted next-generation sequencing as a biomarker in hepatocellular carcinoma Bertin Technologies 69981](https://www.bertin-technologies.com/wp-content/uploads/2024/06/governance.png){kind=small}
![[PUBLICATION PRECELLYS] Qualification of tumour mutational burden by targeted next-generation sequencing as a biomarker in hepatocellular carcinoma Bertin Technologies 69990](https://www.bertin-technologies.com/wp-content/uploads/2024/06/business-units.png){kind=small}
![[PUBLICATION PRECELLYS] Qualification of tumour mutational burden by targeted next-generation sequencing as a biomarker in hepatocellular carcinoma Bertin Technologies 69987](https://www.bertin-technologies.com/wp-content/uploads/2024/06/subsidiaries.png){kind=small}
![[PUBLICATION PRECELLYS] Qualification of tumour mutational burden by targeted next-generation sequencing as a biomarker in hepatocellular carcinoma Bertin Technologies 69997](https://www.bertin-technologies.com/wp-content/uploads/2024/06/location.png){kind=small}
![[PUBLICATION PRECELLYS] Qualification of tumour mutational burden by targeted next-generation sequencing as a biomarker in hepatocellular carcinoma Bertin Technologies 70000](https://www.bertin-technologies.com/wp-content/uploads/2024/06/certifications.png){kind=small}
Abstract
Background & Aims
Tumour mutational burden (TMB) predicts improved response and survival to immunotherapy. In this pilot study, we optimized targeted next-generation sequencing (tNGS) to estimate TMB in hepatocellular carcinoma (HCC).
Methods
We sequenced 48 non-paired samples (21 fresh-frozen [FF] and 27 paraffin-embedded [FFPE]), among which 11 FFPE samples were pretreated with uracil-DNA glycosylase (UDG). Thirty samples satisfied post-sequencing quality control. High/low TMB was defined by median number of mutations/Mb (Mut/Mb), across different minimum allele frequency (MAF) thresholds (=0.05, =0.1 and =0.2).
Results
Eligible patients (n = 29) were cirrhotic (84%) with TNM stage I-II HCC (75%). FFPE samples had higher TMB (median 958.39 vs 2.51 Mut/Mb, P < .0001), estimated deamination counts (median 1335.50 vs 0, P < .0001) and C > T transitions at CpG sites (median 60.3% vs 9.1%, P = .002) compared to FF. UDG-treated samples had lower TMB (median 4019.92 vs 353 Mut/Mb, P = .041) and deamination counts (median 6393.5 vs 328.5, P = .041) vs untreated FFPE. At 0.2 MAF threshold with UDG treatment, median TMB was 5.48 (range 1.68-16.07) and did not correlate with salient pathologic features of HCC, including survival.
Conclusion
While tNGS on fresh HCC samples appears to be the optimal source of tumour DNA, the low median TMB values observed may limit the role of TMB as a predictor of response to immunotherapy in HCC.
